BioCardia
BioCardia is developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
BioCardia is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Its lead program is CardiAMP® autologous mononuclear cell therapy for ischemic heart failure of reduced ejection fraction (HFrEF). The company also has a pipeline including CardiALLO™ and PulmALLO™.
History
BioCardia is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Its lead program is CardiAMP® autologous mononuclear cell therapy for ischemic heart failure of reduced ejection fraction (HFrEF). The company also has a pipeline including CardiALLO™ and PulmALLO™.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/biocardia · Editorial policy · How profiles are compiled